SCOTTSDALE, Ariz., July 3, 2008 (PRIME NEWSWIRE) -- TASER International, Inc. (Nasdaq:TASR), a market leader in advanced electronic control devices, announced that four abstracts reporting on human testing on the safety of TASER(r) electronic control devices (ECDs) were presented at Australasian College for Emergency Medicine Winter Symposium 2008 during July 2-4 in Newcastle, New South Wales. The Australasian College for Emergency Medicine is an incorporated educational institution whose prime objective is the training and examination of specialist emergency physicians for Australia and New Zealand and the ongoing Maintenance of Professional Standards.
The four abstracts reporting data from human studies of TASER electronic control devices and their conclusions are:
The Effect of Cross Chest Electronic Control Device Exposure on Breathing.
"This study demonstrates that the cross-chest exposure does not significantly impair respiratory function."
Donald Dawes, MD, Jeffrey Ho, MD and James Miner, MD. Hennepin
County Medical Center, Minneapolis, MN.
The Effect of the eXtended Range Electronic Projectile (XREP) on Breathing.
"This study demonstrates that the XREP does not significantly impair respiratory functions."
Donald Dawes, MD, Jeffrey Ho, MD, Jeremy Olsen, MD and
James Miner, MD. Hennepin County Medical Center, Minneapolis, MN.
Echocardiographic Determination of Cardiac Rhythm During Trans-Thoracic Wireless Conducted Electrical Weapon Exposure.
"Although motion artifact limited a few of the evaluations, we were able to document sinus rhythm in over half of the subjects and were able to obtain heart rates in all but three. In all but those three subjects, we saw no evidence of myocardial capture or arrhythmia during a 20-second trans-thoracic XREP exposure."
Jeffrey Ho, MD, Donald Dawes, MD, Robert Reardon, MD,
Anne Lapine, MD and James Miner, MD. Hennepin County Medical
Center, Minneapolis, MN.
Cardiac and Diaphragm ECHO Evaluation during TASER Device Drive Stun.
"We did not find a connection between measureable, worsening human physiology and ECD DS exposure. This work is consistent with previously reported findings of human ECD studies utilizing deployed probe methodology."
Jeffrey Ho, MD, Donald Dawes, MD, Robert Reardon, MD,
Ronald Moscati, MD, Rebecca Gardner, BS and James Miner, MD.
Hennepin County Medical Center, Minneapolis, MN, Meeker County
Sheriff's Office, Litchfield, MN, Lompoc District Hospital,
Lompoc, CA, Santa Barbara Police Department, Santa Barbara, CA,
SUNY at Buffalo, Buffalo, NY.
For more information about Australasian College for Emergency Medicine Winter Symposium 2008 visit: http://www.acem.org.au.
About TASER International, Inc.
TASER International's products protect life. TASER provides advanced Electronic Control Devices (ECDs) for use in the law enforcement, medical, military, corrections, professional security, and personal protection markets. TASER devices use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. For more information please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
The TASER International logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2931
Note to Investors
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. These statements are qualified by important factors that could cause our actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) market acceptance of our products; (2) our ability to establish and expand direct and indirect distribution channels; (3) our ability to attract and retain the endorsement of key opinion-leaders in the law enforcement community; (4) the level of product technology and price competition for our products; (5) the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; (6) risks associated with rapid technological change and new product introductions; (7) competition; (8) litigation including lawsuits resulting from alleged product related injuries and death; (9) media publicity concerning allegations of deaths and injuries occurring after use of the TASER device and the negative effect this publicity could have on our sales; (10) TASER device tests and reports; (11) product quality; (12) implementation of manufacturing automation; (13) potential fluctuations in our quarterly operating results; (14) financial and budgetary constraints of prospects and customers; (15) order delays; (16) dependence upon sole and limited source suppliers; (17) negative reports concerning the TASER device; (18) fluctuations in component pricing; (19) government regulations and inquiries; (20) dependence upon key employees and our ability to retain employees; (21) execution and implementation risks of new technology; (22) ramping manufacturing production to meet demand; (23) medical and safety studies; (24) field test results; and (25) other factors detailed in our filings with the Securities and Exchange Commission, including, without limitation, those factors detailed in the Company's Annual Report on Form 10-K and its Form 10-Qs.
The statements made herein are independent statements of TASER International. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.